Indian pharmaceutical companies report mixed Q2 earnings

Major Indian pharmaceutical firms reported divergent financial results for the September quarter. Neuland Laboratories Limited saw a 47 percent year-on-year decline in net profit, falling to Rs 51.6 crore from Rs 96.9 crore in the previous year. This decline was accompanied by a 12.5 percent drop in revenue from operations, which totaled Rs 449.7 crore.

Sun Pharmaceutical Industries reported a 36.36 percent decrease in consolidated net profit to Rs 1,988.53 crore. Despite the profit drop, the company's total revenue rose to Rs 16,198.71 crore, up from Rs 14,478.31 crore a year earlier. The profit decline was attributed to approximately Rs 1,269 crore in exceptional charges, including a Rs 923 crore settlement for US generic-pricing antitrust litigation and costs related to the proposed acquisition of Organon.